The first clinical trial of the Nazi vaccine against Alzheimer's disease begins

The first clinical trial of the Nazi vaccine against Alzheimer's disease begins

This is the culmination of almost 20 years of research, and Boston Hospital Brigham and Women's Hospital has announced the beginning of a clinical trial to test the safety and effectiveness of a new Nazi vaccine.

Alzheimer ' s disease is the most common cause of dementia; it results from the accumulation of amyloid sediments and the progressive degeneration of neurons and is characterized by a deterioration in memory and executive functions, a lack of thought and disorientation, and there is no treatment to date, but research in this area has been particularly fruitful in recent years and has led to a better understanding of the disease, in particular risk factors and physiological mechanisms.

Phase 1 will involve 16 people between the ages of 60 and 85, all with an early stage of Alzheimer ' s disease, but with a good general state of health, who will receive two doses of one-weekly vaccine, reported to the hospital. As in any phase 1 test, the purpose of the study is to determine the safety and transportability of the Nazi vaccine. Researchers will also assess the impact of the protollin on the participant ' s immune response.

Incentives of the immune system

The vaccine uses a Protollin immunomodulator, an experimental intranazial drug that stimulates the immune system, which can help combat certain diseases. A study published in 2004 showed that this adjuwante, combined with influenza antigens, increases the rate of serum immunoglobulin by a factor of 250 compared to the immunization of only antigens. The protein produced from bacteria has already been safely used in humans as an adjuant for other vaccines.

Scientists hope that in the same way he will be able to activate the body's immune system to affect beta-amyloid protein fleas

Protollin is designed, produced and sold by two Chinese pharmaceutical companies I-Mab Biopharma and Jiangsu Nhwa Pharmacetical to migrate into the brain and remove beta-amyloid plaques. " said Tanuja Chitnis, professor of neurology at Brigham Hospital and women's hospital, and chief researcher of the trial.

This token human test will enable the research group to measure the impact of the Nazi protollin on the immune response, in particular its impact on white blood cells, by examining cell surface markers, genetic profiles and functional tests. ", says Howard Weiner.

Several treatment methods are being developed

According to the National Institute of Ageing, Alzheimer's disease is the sixth leading cause of death in the United States, and researchers around the world have worked over the years to develop new drugs to treat or slow Alzheimer's disease, and often experimental drugs can eliminate amyloid plaque, but do not eliminate daily symptoms in patients with very severe disabilities, namely loss of autonomy and reduced cognitive ability.

Research has recently developed a cure and vaccine against this disease, which is very promising in mice, and their approach is different from that of other experimental treatments because they target a very specific form of amyloid-beth protein. Although the results are very encouraging, it will unfortunately take years of research before people get treated.

In June, the Food and Drug Control Authority approved the first new drug for Alzheimer's disease in 20 years: Aduelm, developed by the American Biogen Laboratory in collaboration with the Japanese company Eisai Co.

The FDA decision was therefore mixed, especially after independent consultants had warned that the drug had not proved that it was actually helping to slow down the disease, and it also entailed the risk of serious side effects.